Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 13/20 | 0.40 |
| ▸ | SETDB1 | Q15047 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 5/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9896878 | 0.93 | GRM2 (0.40) | GRM2HTR2AHTR2CSLC6A4CRHR1 | |
| SCHEMBL9926867 | 0.90 | GRM2 (0.38) | GRM2HTR2AHTR2CSLC6A4CRHR1 | |
| SCHEMBL9926889 | 0.90 | GRM2 (0.38) | GRM2HTR2AHTR2CSLC6A4 | |
| SCHEMBL9896457 | 0.89 | GRM2 (0.37) | GRM2 | |
| SCHEMBL9926787 | 0.88 | GRM2 (0.46) | GRM2HTR2AHTR2CSLC6A4CRHR1 | |
| SCHEMBL9896427 | 0.88 | ROCK2 (0.39) | GRM2CRHR1CRHR2 | |
| SCHEMBL9894894 | 0.87 | AR (0.38) | GRM2HTR2AHTR2CSLC6A4CRHR1 | |
| SCHEMBL9896286 | 0.87 | ALDH1A1 (0.36) | GRM2CRHR1CRHR2 | |
| SCHEMBL9896564 | 0.87 | GRM2 (0.35) | GRM2HTR2AHTR2CSLC6A4CRHR1 | |
| SCHEMBL9896667 | 0.87 | GRM2 (0.35) | GRM2HTR2AHTR2CSLC6A4CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975286-B2 | Ether benzotriazole derivatives | MERCK SHARP & DOHME CORP. (US) | 2015-03-10 | — | — | US | claimed |
| EP-2470527-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2012-07-04 | — | — | EP | claimed |
| US-20120149677-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | MERCK SHARP & DOHME LLC | 2012-06-14 | — | — | US | claimed |
| US-8975286-B2 | Ether benzotriazole derivatives | MERCK SHARP & DOHME CORP. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975286-B2 | Ether benzotriazole derivatives | MERCK SHARP & DOHME CORP. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20120149677-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | MERCK SHARP & DOHME LLC | 2012-06-14 | — | — | US | disclosed |
| US-20120149677-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | MERCK SHARP & DOHME LLC | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149677-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | GRM2, GRIA2, GRIK2 | GRM2 1/4885SETDB1 3045/4885HTR2A 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.